Incidence and treatment of no-reflow after percutaneous coronary intervention. Circulation. 1994; 89:2514 8. 685. Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to rep- erfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45:1775 80. 686. Sdringola S, Assali A, Ghani M, et al. Adenosine use during aorto- coronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv. 2000;51: 394 9. 687. Stoel MG, Marques KM, de Cock CC, et al. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv. 2008;71: 283 9. 688. Werner GS, Lang K, Kuehnert H, et al. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocar-dial infarction. Catheter Cardiovasc Interv. 2002;57:444 51. 689. Weyrens FJ, Mooney J, Lesser J, et al. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol. 1995; 75:849 50. 690. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients data with long-term follow-up. Eur Heart J. 2007;28:443 9. 691. Fischell TA, Carter AJ, Foster MT, et al. Reversal of no reflow during vein graft stenting using high velocity boluses of intracoronary adeno- sine. Cathet Cardiovasc Diagn. 1998;45:360 5. Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e637 692. Skelding KA, Goldstein JA, Mehta L, et al. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv. 2002;57:305 9. 693. Iwasaki K, Samukawa M, Furukawa H. Comparison of the effects of nicorandil versus verapamil on the incidence of slow flow/no reflow during rotational atherectomy. Am J Cardiol. 2006;98:1354 6. 694. Matsuo H, Watanabe S, Watanabe T, et al. 